08.13.24
Champalimaud Foundation, a biomedical clinical research organization, has installed Lonza’s MODA-ES Platform at the Champalimaud Clinical Centre in Lisbon, Portugal.
Through the installation of MODA-ES, the Champalimaud Foundation aims to improve and streamline the cell therapy manufacturing process to improve accessibility for cancer therapies.
In collaboration with academic and industry partners, the Champalimaud Foundation has built a state-of-the-art multipurpose GMP facility to develop biologically and clinically promising cell therapies with industrial standards. The foundation sought a paperless solution to ensure the safety of cell production, provide transparency for current and future partners, and monitor the complex production process from reagent purchase to final product release.
The Champalimaud Foundation selected Lonza’s MODA-ES Platform, a configurable manufacturing execution system (MES) designed specifically for cell and gene therapy production. It consolidates all manufacturing batch and batch-related quality control data into a single record for reduced errors, greater visibility, and expedited product release. The platform provides advanced traceability and genealogy workflows, which helps to ensure the chain of identity and custody in complex decentralized cell and gene therapy manufacturing processes.
Orla Cloak, Senior Vice President, Head of Bioscience, Lonza, said, “We are committed to supporting our customers in bringing innovative cell and gene therapies to their patients. This commitment relies on our capability to offer the right expertise and tools, including MODA-ES®. We are also proud to support our customers with an experienced implementation team that understands the intricacies of cell and gene therapy manufacture and can help to accelerate the path to market for these novel therapies.”
Through the installation of MODA-ES, the Champalimaud Foundation aims to improve and streamline the cell therapy manufacturing process to improve accessibility for cancer therapies.
In collaboration with academic and industry partners, the Champalimaud Foundation has built a state-of-the-art multipurpose GMP facility to develop biologically and clinically promising cell therapies with industrial standards. The foundation sought a paperless solution to ensure the safety of cell production, provide transparency for current and future partners, and monitor the complex production process from reagent purchase to final product release.
The Champalimaud Foundation selected Lonza’s MODA-ES Platform, a configurable manufacturing execution system (MES) designed specifically for cell and gene therapy production. It consolidates all manufacturing batch and batch-related quality control data into a single record for reduced errors, greater visibility, and expedited product release. The platform provides advanced traceability and genealogy workflows, which helps to ensure the chain of identity and custody in complex decentralized cell and gene therapy manufacturing processes.
Orla Cloak, Senior Vice President, Head of Bioscience, Lonza, said, “We are committed to supporting our customers in bringing innovative cell and gene therapies to their patients. This commitment relies on our capability to offer the right expertise and tools, including MODA-ES®. We are also proud to support our customers with an experienced implementation team that understands the intricacies of cell and gene therapy manufacture and can help to accelerate the path to market for these novel therapies.”
